Have you noticed your polycythemia vera (PV) impacting the things you enjoy doing? You may blame the way you feel on getting older, but it could mean that your PV is getting worse. It's time to help take control of your PV and discover your path to possible. Talk to your doctor to find out if Jakafi® (ruxolitinib) is right for you.
This video is intended for informational use only and is not designed to replace the medical advice of your healthcare professional. Jakafi is a prescription medicine used to treat adults with PV who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
In a clinical trial of patients with PV, Jakafi kept the volume of red blood cells under control, reducing the need for phlebotomy, and reduced spleen size.
Selected Safety Information
Jakafi can cause serious side effects, including low blood counts and infection. Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of myelofibrosis and PV include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects.
To learn more about these and other risks, please read the Important Safety Information at www.jakafi.com/polycythemia-vera/.
Please see the Full Prescribing Information www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to lncyte Medical Information at 1-855-463-3463.
For information, support, and resources about Jakafi, visit www.jakafi.com/register-forresources.
Jakafi® (ruxolitinib) is available in 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg tablets.
Jakafi, the Jakafi logo, Incyte, and the Incyte logo are registered trademarks of Incyte.
© 2024, Incyte. MAT-JAK-04970 04/24